EUCTR2020-004694-46-LV进行中（未招募）1 期
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD) - COAST
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Opthea
- 入组人数
- 990
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male or female participants at least 50 years of age.
- •Active subfoveal CNV lesion or juxtafoveal CNV lesion with foveal involvement that is secondary to AMD in the Study Eye.
- •An ETDRS BCVA score between 60 and 25 (inclusive) letters in the Study Eye.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 890
排除标准
- •Any previous treatment for neovascular AMD.
- •Clinically significant ocular disorders (other than neovascular AMD), which may interfere with assessment of BCVA, assessment of safety, or fundus imaging.
- •Any current (or history of a) social, psychological, or medical condition that precludes enrolment into the study.
- •Note: other protocol exclusion criteria may also apply.
研究者
相似试验
进行中（未招募）
1 期
Research study of Rolapitant versus Placebo for the prevention of nausea and vomiting related to chemotherapy that has a high likelihood of inducing nausea and vomiting.Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Highly Emetogenic Chemotherapy (HEC)MedDRA version: 14.1 Level: PT Classification code 10054133 Term: Prophylaxis of nausea and vomiting System Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 14.1 Level: LLT Classification code 10049091 Term: Chemotherapy antiemetic prophylaxis System Organ Class: 10042613 - Surgical and medical proceduresEUCTR2010-022742-25-ESTesaro, Inc.526
进行中（未招募）
不适用
Research study of Rolapitant versus Placebo for the prevention of nausea and vomiting related to chemotherapy that has a high likelihood of inducing nausea and vomiting.Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Highly Emetogenic Chemotherapy (HEC)MedDRA version: 16.0Level: PTClassification code 10054133Term: Prophylaxis of nausea and vomitingSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 16.0Level: LLTClassification code 10049091Term: Chemotherapy antiemetic prophylaxisSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2010-022742-25-PTTesaro, Inc.530
进行中（未招募）
不适用
AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastricor Esophagogastric Junction CancerEUCTR2011-004923-11-ITAMGEN INC.450
进行中（未招募）
不适用
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE-2) - ILLUMINATE-2Systemic Lupus Erythematosus (SLE)MedDRA version: 14.1Level: LLTClassification code 10025139Term: Lupus erythematosus systemicSystem Organ Class: 100000004859EUCTR2010-022100-42-HUEli Lilly and Company1,140
进行中（未招募）
不适用
Study Evaluating the Efficacy and Safety of Bapineuzumab in Alzheimer Disease Patients Who Are Apolipoprotein E e4 CarriersAlzheimer DiseaseMedDRA version: 14.1Level: PTClassification code 10012271Term: Dementia Alzheimer's typeSystem Organ Class: 10029205 - Nervous system disordersEUCTR2007-005995-14-FIWyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA1,100